Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Retrieved on:
Wednesday, March 2, 2022
Amifampridine, Patient, LEMS, Adult, Patent, Population, Forward-looking statement, Seminal vesicles, K, Annual report, Tablet, United, FDA, New Drug Application, Exocytosis, NAT2, SEC, Company, Lambert–Eaton myasthenic syndrome, CORAL, Catalyst Pharmaceuticals, Potassium, Approved Drug Products with Therapeutic Equivalence Evaluations, USPTO, GLOBE, Degenerative disease, Pharmaceutical industry, Catalysis, Acetylcholine
CORAL GABLES, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has notified Catalyst that an additional patent covering FIRDAPSE® (amifampridine) Tablets 10 mg, the Company's proprietary formulation of amifampridine, will issue on March 8, 2022, and that two additional patents will issue on March 15, 2022. FIRDAPSE is currently the only approved treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") in the U.S.
Key Points:
- FIRDAPSE is currently the only approved treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") in the U.S.
- "As part of our portfolio strategy, we will continue to execute on our key initiatives to strengthen and protect the long-term commercial potential of FIRDAPSE, which currently has patent exclusivity protection in the U.S. until 2034."
- Copies of Catalyst's filings with theSECare available from theSEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst.
- Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.